Considering the recent development and success of immunotherapy to stop cancer progression and the well-documented role of Gal-1 in the control of the immune response, most notably against cancer killing immune cells, it is reasonable to predict an increased interest in investigating whether inhibition of Gal-1 may help to improve the success rate of immunotherapy against glioma. The gene discussed is GAL; the disease is central nervous system cancer.